futibatinib   Click here for help

GtoPdb Ligand ID: 9786

Synonyms: Example 2 [WO2013108809] | FGFR-IN-1 | Lytgobi® | TAS 120 | TAS-120 | TAS120
Approved drug PDB Ligand
futibatinib is an approved drug (FDA (2022), EMA (2023))
Compound class: Synthetic organic
Comment: Futibatinib (TAS-120) is a covalent (irreversible), non-selective FGFR inhibitor that was developed for anti-tumour activity [5]. It is claimed as Example 2 in patent WO2013108809 [4]. It can overcome acquired resistance to ATP-competitive FGFR inhibitors (such as infigratinib and zoligratinib) in intrahepatic cholangiocarcinomas that harbour FGFR2 kinase domain mutations [2]. A case study in a patient with metastatic cholangiocarcinoma, whose tumour had a FGFR2-CORO2B gene fusion and a pemigatinib-induced resistance mutation, demonstrated tumour shrinkage in response to futibatinib treatment [3].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 5
Topological polar surface area 108.39
Molecular weight 418.18
XLogP 2.77
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C=CC(=O)N1CCC(C1)n1nc(c2c1ncnc2N)C#Cc1cc(OC)cc(c1)OC
Isomeric SMILES C=CC(=O)N1CC[C@@H](C1)n1nc(c2c1ncnc2N)C#Cc1cc(OC)cc(c1)OC
InChI InChI=1S/C22H22N6O3/c1-4-19(29)27-8-7-15(12-27)28-22-20(21(23)24-13-25-22)18(26-28)6-5-14-9-16(30-2)11-17(10-14)31-3/h4,9-11,13,15H,1,7-8,12H2,2-3H3,(H2,23,24,25)/t15-/m0/s1
InChI Key KEIPNCCJPRMIAX-HNNXBMFYSA-N
No information available.
Summary of Clinical Use Click here for help
TAS-120 was advanced to clinical evaluation in solid tumours and multiple myeloma (MM), with FGFR gene abnormalities. EMA orpahn designation was issued in April 2019, which authorised futibatinib as a treatment for cholangiocarcinoma (biliary tract cancer). First FDA approval was granted in September 2022, which indicated futibatinib (Lytgobi) for the treatment of previously treated, unresectable, locally advanced/metastatic intrahepatic cholangiocarcinoma (iCCA; with confirmed FGFR2 gene fusions or other rearrangements).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02052778 A Study of TAS-120 in Patients With Advanced Solid Tumors Phase 1/Phase 2 Interventional Taiho Oncology, Inc. 1